Article Text

Download PDFPDF
Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In patients with type 2 diabetes, is rosiglitazone (RGZ) as add on therapy non-inferior to metformin (MFN) plus sulphonylurea (SFU) for cardiovascular (CV) outcomes?

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 2007;357:28–38.

Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Cardiology ★★★★★★⋆ Endocrine ★★★★★★⋆ Internal medicine ★★★★★⋆⋆


Embedded ImageDesign:

randomised controlled trial (RCT) (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes [RECORD] trial).

Embedded ImageAllocation:

unclear allocation concealment.*

Embedded ImageBlinding:

blinded (outcome assessors).*

Embedded ImageFollow-up period:

mean 3.75 …

View Full Text


  • Source of funding: GlaxoSmithKline.